Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Cardiogenomics Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The cardiogenomics industry has witnessed substantial expansion lately, projecting a rise from $1.74 billion in 2025 to $2.02 billion in 2026, fueled by a compound annual growth rate of 15.7%. Factors contributing to this historical expansion include the escalating incidence of heart ailments, groundbreaking progress in genetic analysis tools, increased investment in cardiovascular genomic studies, broader accessibility to molecular diagnostic methods, and heightened public understanding of hereditary cardiac issues.
The cardiogenomics market is poised for substantial expansion over the coming years, projected to reach a valuation of $3.57 billion by 2030 with a compound annual growth rate of 15.4%. This anticipated growth is fueled by several key drivers, including a heightened demand for individualized cardiac care, the broadening scope of precision medicine efforts, escalating investments in genomic research, the increasing utilization of artificial intelligence for genomic analysis, and a greater incorporation of genomics into the standard practice of cardiology. Key developments anticipated during this forecast period encompass a greater embrace of genetic risk assessment within cardiology, a surge in the application of next-generation sequencing for investigating heart conditions, enhanced integration of bioinformatics tools, the development of more tailored cardiovascular treatment strategies, and an amplified emphasis on proactive genomic screening.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28156&type=smp
Cardiogenomics Market Opportunity Drivers: What Is Creating New Revenue Potential?
The expansion of the cardiogenomics sector is anticipated to be significantly influenced by the growing need for personalized medical care. This approach to healthcare customizes preventative measures, diagnostic processes, and therapeutic interventions based on an individual’s genetic makeup, environmental exposures, and lifestyle choices. Progress in genomics fuels the adoption of personalized medicine, fostering a more profound comprehension of genetic differences among individuals and paving the way for treatments that are not only more accurate and targeted but also enhance patient results while minimizing the guesswork in therapeutic strategies. Cardiogenomics contributes to this trend by leveraging genetic information to customize the prevention, diagnosis, and treatment of cardiovascular ailments according to each person’s distinct genetic blueprint. Illustratively, in February 2024, data from the Personalized Medicine Coalition, a U.S.-based nonprofit, indicated that in 2023, the FDA authorized 16 novel personalized therapies for individuals with rare diseases, a notable increase from the six approvals seen in 2022. These recently authorized personalized treatments for 2023 further encompass seven oncology medications and three for various other ailments and conditions. Consequently, the rising demand for personalized medicine is acting as a key catalyst for the growth observed in the cardiogenomics market.
Cardiogenomics Market Segment Breakdown: Which Categories Generate The Most Revenue?
The cardiogenomics market covered in this report is segmented –
1) By Product Type: Testing Kits, Reagents, Instruments, Software, Services
2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Microarray, Other Technologies
3) By Application: Congenital Heart Diseases, Cardiomyopathies, Arrhythmias, Coronary Artery Disease, Other Applications
4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Other End-Users
Subsegments:
1) By Testing Kits: PCR (Polymerase Chain Reaction) kits, Microarray kits, NGS (Next Generation Sequencing) kits
2) By Reagents: Enzymes, Probes, Buffers
3) By Instruments: Sequencers, Genotyping instruments, Microarray Scanners
4) By Software: Data Analysis Software, Reporting Platforms, Bioinformatics Tools
5) By Services: Genetic Testing Services, Counseling Services, Data Analysis Services
Cardiogenomics Market Innovation Trends Driving Future Development
Leading players within the cardiogenomics sector are prioritizing the creation of novel approaches, including oncogenomics, aimed at improving the early identification and tailored treatment strategies for cancers associated with the heart. Oncogenomics, as a discipline, involves the investigation of genes implicated in cancer and their associated changes, with the goal of comprehending how cancer emerges and progresses, and subsequently devising therapies that are precisely targeted and individualized. A notable development in this area occurred in April of 2025 when Fortis Healthcare Ltd., an Indian healthcare provider, established the Fortis Institute of Genomic Medicine in India, dedicated to furthering genetic research and the practice of personalized medicine. This initiative is designed to revolutionize patient care by facilitating the prompt detection of diseases, ensuring accurate diagnoses, and providing individualized treatment plans across various medical fields, including oncology, cardiology, and neurology. It facilitates the implementation of therapies directed at specific targets, thereby enhancing treatment effectiveness and contributing to the prevention of inherited disorders. The fundamental objective of this institute is to propel the field of precision medicine forward through the collaborative efforts of a diverse team and the deployment of cutting-edge technologies, ultimately rendering healthcare more customized and impactful for individuals in India.
Cardiogenomics Market Key Players And Strategic Industry Positioning
Major companies operating in the cardiogenomics market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Illumina Inc., QIAGEN N.V., Myriad Genetics Inc., ARUP Laboratories, BGI Genomics Co. Ltd., Invitae Corporation, GeneDx Inc., Helix OpCo LLC, SOPHiA GENETICS SA, Baylor Genetics, Blueprint Genetics, Novogenia GmbH, Veritas Genetics, Dante Genomics, Gene by Gene Ltd., GENinCode Plc., UAB Cardiogenomics Clinic
Access The Complete Cardiogenomics Market Report:
https://www.thebusinessresearchcompany.com/report/cardiogenomics-global-market-report
Cardiogenomics Market Global Footprint: Which Region Holds Market Leadership?
North Americawas the largest region in the cardiogenomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiogenomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
